David Cutter

Our @glow_nlphl lead Dr. @JamieFlerlage spoke about the GLOW multicenter study of radiation therapy outcomes for Stage IA NLPHL which she presented at #18ICML for @VJHemOnc. #lymsm #NLPHLsm vjhemonc.com/video/amtyhj8p…

If you’re at #ICML2025 come by my poster 1230-1300. We examine survival by anthracycline use in older cHL patients. TLDR: use anthracycline if at all possible! @DavidJCutter @graham74GC

View the latest NNHLA Quarterly Data Dashboard here: bit.ly/4j21CpP @HQIP @JillStoddart @lymphomahub @LLSusa @LymphomaAction @lymphoma @DavidJCutter @NHSEngland @AnthonyNolan @bloodcancer_uk @BloodCancer_Res #data #NHL #Cancer

📢Our latest newsletter provides updates on: State of the Nation reporting, our Quarterly Clinical Performance Indicator report, the recent @NATCAN_news webinar & details of the latest report from @bloodcancer_uk 📰 bit.ly/4i2c1Br @HQIP @LymphomaAction @Ed_Pinches #NHL

Out this week, this new publication explores how the distribution of trial site locations, may lead to disparities in patient representation in clinical trials. bit.ly/416VENC @DavidJCutter @LymphomaAction @bloodcancer_uk @NATCAN_news @WileyGlobal @NHSEngland @HQIP

Having learned every @BritSocHaem guideline off by heart for my FRCPath, it was very exciting to have been afforded the opportunity to lead an amazing group of co-authors for our GPP regarding bleomycin use in Hodgkin Lymphoma- published today! onlinelibrary.wiley.com/doi/10.1111/bj…

Moving beyond mean heart dose: The importance of cardiac substructures in radiation therapy toxicity. onlinelibrary.wiley.com/doi/full/10.11…

The #UKLRG meeting offers opportunities to ask questions, debate issues of interest in clinical practice, hear updates on UK #clinicaltrials and review advances in #lymphoma #radiotherapy techniques. Join us in London 27 Jan: lymphoma-action.org.uk/UKLRG @PattyDiezH @GeorgeMikhaeel

Steve Ansell highlighting late effects of our treatment. No ‘safe dose’ of dox with respect to cardiac toxicity. Good data for dexrazoxane cardio protection with no evidence of ‘tumour protection’. #ISHL13 #lymsm

Abscopal effect does exist in #Hodgkin lymphoma when RT 20Gy is given to PD-1 treated patiens. New distant responses seen outside RT fields. Pembro-RT an option in R/R HL with limited disease #ISHL13 #lymsm dr Christian Bauses. Also safe with RT with low doses! AERN trial !

Thanks to Rajana Advani for including our data in the Best of #ISHL13 session. What a phenomenal three days- so much exciting science and practice-changing trial data, and so many new friends made with exciting future collaboration potential.

Great presentation by @ABarrettHaem on the NHSE dataset of older pts with Hodgkin lymphoma. ABVD assoc with best outcomes but of course used in fitter pts. Profound impact of age, PS, comorbidities in this age group. #ISHL13 #lymsm

Fascinating - the hospital at which a patient with Hodgkin lymphoma is treated in England has more effect on the variation in radiotherapy usage than sex of the patient. Suggests standardisation of approach is not yet achieved! #ISHL13 #lymsm. @DavidJCutter @DavidAdrwJones

Excited to be here at #ISHL13 , come along Sunday at 3pm for my talk about our registry analysis @DavidJCutter and swing by our posters regarding translational analysis of the ANIMATE study and our data collection project HoOP @graham74GC #hodgkinlymphoma

We promised you something exciting was coming... Our first quarterly report which includes clinical performance indicators & is presented on a new,highly interactive dashboard! 💥 bit.ly/3Ni3PyL @HQIP @LymphomaAction @bloodcancer_uk @DavidJCutter @KateWalkerLon #NHL

Watch this space! 👀Our latest NNHLA quarterly report is out tomorrow. We won't spoil the surprise, but we've been working on some changes and this time something is different!..... 🤫🏥📊🔎 @HQIP @JillStoddart @bloodcancer_uk @LymphomaAction @BritSocHaem @DavidJCutter

📢💥It's here! We are delighted to share our first State of the Nation report; along with a number of supplementary materials. Our thanks to everyone involved in its development. bit.ly/3XmI5q7 @HQIP @LymphomaAction @bloodcancer_uk @DavidJCutter @KateWalkerLon

Exciting news! ⭐️The first NNHLA State of the Nation report is out tomorrow! Check this space or the @NATCAN_news webpages for details bit.ly/3TkRE7J #BCAM @LymphomaAction @bloodcancer_uk @LLSusa @AnthonyNolan @HQIP @NHSEngland @DavidJCutter @macmillancancer @MJAhearne

The NNHLA Quality Improvement Plan has landed! The plan sets out: ⭐️5 QI goals ⭐️11 performance indicators Read the full report here bit.ly/3AKNvmX @LymphomaAction @LLSusa @bloodcancer_uk @BritSocHaem @AnthonyNolan @HQIP @JillStoddart @DavidJCutter @KateWalkerLon

We are delighted to share a short blog which has been prepared by our Patient and Public Involvement Chair, Frank Burroughs. Please do take a look. bit.ly/3ANCOQP #BCAM @NATCAN_news @LymphomaAction @bloodcancer_uk @BloodCancerA @BritSocHaem @DavidJCutter @HQIP